📊 MRNA Key Takeaways
Is Moderna, Inc. (MRNA) a Good Investment?
Moderna is experiencing severe operational distress with negative net income of $2.8B, collapsing revenue (-39.9% YoY), and negative free cash flow of $2.1B, indicating the company cannot sustain current operations without burning cash reserves. While the balance sheet provides a liquidity cushion with $2.6B in cash and a healthy 3.29x current ratio, the deteriorating fundamentals suggest fundamental business challenges requiring urgent strategic repositioning.
Fundamentals show steep revenue contraction and heavy losses, with deeply negative operating and free cash flow margins. However, a strong balance sheet with ample liquidity and low leverage provides runway to execute and narrow losses. Await evidence of revenue stabilization and improved operating efficiency before a more constructive stance.
Why Buy Moderna, Inc. Stock? MRNA Key Strengths
- Strong liquidity position with $2.6B cash and 3.29x current ratio provides 12+ months operating runway
- Manageable leverage with 0.07x debt-to-equity ratio limits financial distress risk in near-term
- Net loss improved 20.8% YoY despite revenue collapse, suggesting some cost control efforts
- Ample liquidity (3.29x current, $2.60B cash) supporting runway
- Low leverage (0.07x D/E) and modest long-term debt
- Large equity base ($8.65B) and YoY improvement in net loss
MRNA Stock Risks: Moderna, Inc. Investment Risks
- Operating losses of $3.1B with negative 158.1% operating margin indicate core business is unprofitable and unsustainable
- Revenue declined 39.9% YoY suggesting loss of market demand, potentially from COVID vaccine revenue normalization
- Negative free cash flow of $2.1B with -106.2% FCF margin means company is rapidly depleting cash reserves and cannot self-fund operations
- Negative ROE (-32.6%) and ROA (-22.9%) demonstrate value destruction for shareholders
- Revenue down 39.9% YoY, indicating weak demand momentum
- Sustained negative operating margin (-158%) and FCF margin (-106%)
- Ongoing cash burn with non-meaningful interest coverage raises financing/execution risk
Key Metrics to Watch
- Quarterly revenue trends and vaccine/pipeline revenue mix to assess market recovery
- Monthly cash burn rate to determine cash runway adequacy
- Operating expense reduction progress as path to profitability
- Pipeline advancement and clinical trial results for non-vaccine candidates
- Revenue YoY growth
- Free cash flow
Moderna, Inc. (MRNA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.29x current ratio provides a solid financial cushion.
MRNA Profit Margin, ROE & Profitability Analysis
MRNA vs Healthcare Sector: How Moderna, Inc. Compares
How Moderna, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Moderna, Inc. Stock Overvalued? MRNA Valuation Analysis 2026
Based on fundamental analysis, Moderna, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Moderna, Inc. Balance Sheet: MRNA Debt, Cash & Liquidity
MRNA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Moderna, Inc.'s revenue has grown significantly by 11,274% over the 5-year period, indicating strong business expansion. The most recent EPS of $-12.33 indicates the company is currently unprofitable.
MRNA Revenue Growth, EPS Growth & YoY Performance
MRNA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.0B | $13.0M | $0.03 |
| Q2 2025 | $142.0M | -$825.0M | $-2.13 |
| Q1 2025 | $108.0M | -$971.0M | $-2.52 |
| Q3 2024 | $1.8B | $13.0M | $0.03 |
| Q2 2024 | $241.0M | -$1.3B | $-3.33 |
| Q1 2024 | $167.0M | $79.0M | $0.19 |
| Q3 2023 | $1.8B | $1.0B | $2.53 |
| Q3 2019 | $17.0M | -$80.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Moderna, Inc. Dividends, Buybacks & Capital Allocation
MRNA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Moderna, Inc. (CIK: 0001682852)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MRNA
What is the AI rating for MRNA?
Moderna, Inc. (MRNA) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MRNA's key strengths?
Claude: Strong liquidity position with $2.6B cash and 3.29x current ratio provides 12+ months operating runway. Manageable leverage with 0.07x debt-to-equity ratio limits financial distress risk in near-term. ChatGPT: Ample liquidity (3.29x current, $2.60B cash) supporting runway. Low leverage (0.07x D/E) and modest long-term debt.
What are the risks of investing in MRNA?
Claude: Operating losses of $3.1B with negative 158.1% operating margin indicate core business is unprofitable and unsustainable. Revenue declined 39.9% YoY suggesting loss of market demand, potentially from COVID vaccine revenue normalization. ChatGPT: Revenue down 39.9% YoY, indicating weak demand momentum. Sustained negative operating margin (-158%) and FCF margin (-106%).
What is MRNA's revenue and growth?
Moderna, Inc. reported revenue of $1.9B.
Does MRNA pay dividends?
Moderna, Inc. does not currently pay dividends.
Where can I find MRNA SEC filings?
Official SEC filings for Moderna, Inc. (CIK: 0001682852) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MRNA's EPS?
Moderna, Inc. has a diluted EPS of $-7.26.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MRNA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Moderna, Inc. has a SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MRNA stock overvalued or undervalued?
Valuation metrics for MRNA: ROE of -32.6% (sector avg: 15%), net margin of -145.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MRNA stock in 2026?
Our dual AI analysis gives Moderna, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MRNA's free cash flow?
Moderna, Inc.'s operating cash flow is $-1.9B, with capital expenditures of $192.0M. FCF margin is -106.2%.
How does MRNA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -145.2% (avg: 12%), ROE -32.6% (avg: 15%), current ratio 3.29 (avg: 2).